SABC 2022 Check vacc, page-59

I may be wrong but funding for Check-Vacc is from COH's funding grants. They tend to have a lot of committees and need the money to stretch a long way (a lot of smart people doing smart things..and some not so smart). Which means slow moving. It was likely designed with having an economy of funds also, hence it moving much slower than Vaxinia.

Great news on OnCARlytics, we also know that OnCARlytics will be at a slightly higher starting dose than MAST study. Every positive indication that it works with Amgen's therapy increases the value of Acer-Cell by multiples. A subset of a subset in blood tumours currently (for Acer-Cell) to potentially many solid tumours is the equation here. Worlds first inherently have huge risk and huge upsides.

If first indication around CF33 MAST are positive at the start of November, we will be looking really good across the board.